secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001703057-23-000005
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera Q1 2023 revenue $12M, net loss $0.14 EPS vs $0.59 EPS profit in Q1 2022
--------------------------------------------------------------------------------

- Total revenue $12.2M, down from $316.6M in Q1 2022; net loss $40.1M vs net income $168.6M.
- EPS loss $0.14 basic/diluted versus EPS profit $0.59 basic/0.54 diluted a year ago.
- Partnered program starts reached 101 cumulative (up 20% YoY); 9 molecules in clinic (up from 6).
- R&D spending rose to $52.6M from $26.4M; cash and marketable securities $821.5M.
- Management highlighted T-cell engager platform progress; no guidance provided.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000170305723000005/0001703057-23-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000170305723000005/abcl-20230504.htm
  HTML page:      https://secwatch.observer/filing/0001703057-23-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer